VABOMERE Shows Higher Cure Rate in Patients with CRE Infections Vs. Best Available Therapy

Michael N. Dudley, PharmD, explains how VABOMERE was associated with a higher overall cure rate and lower mortality compared with the best available therapy in patients with CRE infections in a recent trial.

Michael N. Dudley, PharmD, senior vice president and head of R&D at the Medicines Company, discusses the results of the TANGO II study of VABOMERE, a new beta-lactam that combines meropenem and vaborbactam. In patients with carbapenem-resistant Enterobacteriaceae (CRE), VABOMERE was associated with a higher overall cure and lower mortality compared with the best available therapy.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.